Likewise, Samstein et al. applied the 80th percentile per cancer type (ranging between 4.4 mut/Mb and 52.2 mut/Mb) as the cutoff in defining TMB-high, which was shown to be predictive of OS benefits from anti-PD-(L) 1 or anti-CTLA4 therapies among various advanced cancers (Samstein et al., 2019). Here, CTLA4 is linked to cancer.